C-ATJCRNA-binding proteins, AUF1, muscle regeneration
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Use AUF1 gene delivery to improve muscle repair, regeneration, and function in muscle loss conditions.
AAV-based gene therapy delivery of AUF1-related therapeutic payloads.
Listed as AAV lead programs; AUF1 gene transfer has published preclinical evidence in adult mice.
AUF1 gene transfer was reported to increase exercise performance and improve skeletal muscle deficits in adult mice.
Deliver AUF1-based RNA-binding protein therapy to restore or regenerate functional muscle.
Lipid nanoparticle delivery approach for AUF1 therapeutic payloads.
Listed in Regerna's pipeline as an AUF1 LNP approach.
Develop RNA-binding protein therapeutics that restore and regenerate functional muscle lost through aging, injury, and muscular dystrophies by targeting AUF1 as a master controller of muscle repair and regeneration.
RNA-binding protein therapeutic platform focused on AUF1 regulation of RNA stability, splicing, translation, and muscle repair biology.
AUF1 identified as Regerna's lead therapeutic and platform focus, with LNP and AAV program approaches listed.
Supplied publications report AUF1-related effects in muscle regeneration, skeletal muscle integrity, exercise performance, and severe muscle injury models.
Treat Duchenne Muscular Dystrophy by restoring or improving functional muscle through Regerna's AUF1-centered regenerative therapeutic approach.
AUF1-related therapeutic program for Duchenne Muscular Dystrophy; delivery modality not fully specified in the supplied material.
Listed as a program for Duchenne Muscular Dystrophy.